Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.